SCHEMBL7476838

SCHEMBL7476838

NC(=O)OC(=O)NC[C@@H](O)c1ccc(Cl)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCAT2 O15382 1/20 0.47
NPC1 O15118 4/20 0.41
RAB9A P51151 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
LMNA P02545 3/20 0.41
AOC3 Q16853 2/20 0.41
CYP1A2 P05177 2/20 0.39
CYP2C9 P11712 3/20 0.39
CYP2C19 P33261 2/20 0.39
MAPT P10636 1/20 0.39
KDM4E B2RXH2 1/20 0.37
TAAR1 Q96RJ0 1/20 0.37
HDAC4 P56524 1/20 0.37
HDAC7 Q8WUI4 1/20 0.37
HDAC5 Q9UQL6 1/20 0.37
GABBR2 O75899 3/20 0.36
GABBR1 Q9UBS5 3/20 0.36
CYP3A4 P08684 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
NFKB1 P19838 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7460922 1.00 BCAT2 (0.47) BCAT2NPC1RAB9ASMN1; SMN2LMNA
SCHEMBL5248171 0.84 BCAT2 (0.68) BCAT2NPC1RAB9ASMN1; SMN2LMNA
SCHEMBL7466075 0.83 ADRB3 (0.48) BCAT2CYP1A2CYP2C9CYP2C19CYP2D6
SCHEMBL7466916 0.83 ADRB3 (0.48) BCAT2CYP1A2CYP2C9CYP2C19CYP2D6
SCHEMBL7474893 0.83 ADRB3 (0.48) BCAT2CYP1A2CYP2C9CYP2C19CYP2D6
SCHEMBL7459877 0.82 MAPT (0.40) LMNACYP1A2CYP2C9CYP2C19MAPT
SCHEMBL7464034 0.82 MAPT (0.40) LMNACYP1A2CYP2C9CYP2C19MAPT
SCHEMBL7470481 0.82 MAPT (0.40) LMNACYP1A2CYP2C9CYP2C19MAPT
SCHEMBL3657534 0.78 GAA (0.48) NPC1RAB9ASMN1; SMN2LMNAMAPT
SCHEMBL7460467 0.78 BCAT2 (0.40) BCAT2NPC1RAB9ASMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0907635-B1 HALOGEN SUBSTITUTED CARBAMATE COMPOUNDS FROM 2-PHENYL-1,2-ETHANEDIOL SK CORP (KR) 2002-09-25 EP disclosed
US-20010034365-A1 Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol CHOI YONG MOON (US) 2001-10-25 US disclosed
US-6127412-A TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM, ESPECIALLY AS ANTICONVULSANTS, ANTIEPILEPTIC AND NEUROPROTECTIVE AGENTS AND CENTRALLY ACTING MUSCLE RELAXANTS SK CORPORATION (US) 2000-10-03 US disclosed
US-6103759-A COMPRISING PURE ENANTIOMERIC FORMS, AS WELL AS ENANTIOMERIC MIXTURES, OF (2-(2-CHLOROPHENYL)-2-HYDROXYETHYL)OXYCARBOXAMIDE; USEFUL FOR TRATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS SK CORPORATION (US) 2000-08-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010034365-A1 Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol DDT, GRIK2, GABRD BCAT2 603/4885NPC1 1768/4885RAB9A 3412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.